DNA repair enzymes and cytotoxic effects of temozolomide: Comparative studies between tumor cells and normal cells of the immune system

Journal of Chemotherapy

Volumn 15, Issue 2, 2003, Pages 173-183

  Pagani, E ^a   Pepponi, R ^a   Fuggetta, M P ^b   Prete, S P ^c   Turriziani, M ^c   Bonmassar, L ^a   Lacal, P M ^a   Falcinelli, S ^a   Passarelli, F ^a   Guadagni, F ^d   Alvino, E ^b   D'Atri, Stefania ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Alkytransferase; CD1b; LAK; Mismatch repair; Neoplasia; NK; Temozolomide

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; ANTIMITOTIC AGENT; CD1 ANTIGEN; CYTOKINE; DNA; INTERLEUKIN 2; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME BLOOD LEVEL; ENZYME REGULATION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LYMPHOCYTE FUNCTION; LYMPHOKINE ACTIVATED KILLER CELL; MISMATCH REPAIR; MONONUCLEAR CELL; NATURAL KILLER CELL; PROTEIN FUNCTION; PROTEIN INDUCTION; TUMOR CELL; TUMOR IMMUNITY;

EID: 0038627968     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.2.173     Document Type: Article

References (62)

1. Ames BN, Gold LS. Endogenous mutagens and the causes of aging and cancer. Mutat Res 1991; 250: 3-16.
2. Simic MG. DNA markers of oxidative processes in vivo: relevance to carcinogenesis and anticarcinogenesis. Cancer Res 1994; 54 (suppl.): 1918s-1923s.
3. Gerson BL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002; 20: 2388-2399.
4. 6-alkylguanine - DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119-6129.
5. 6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosourea. Cancer Res 1984; 44: 2467-2474.
6. 6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat Res 1985; 145: 1-16.
7. 6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 1995; 9: 1888-1895.
8. 6-alkylguanine DNA alkyltransferase levels: Studies with blast of leukaemic patients. Ann Oncol 1995; 6: 389-393.
9. 6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 1997; 52: 249-258.
10. Jiricny J. and Nystrom-Lahti M. Mismatch repair defects in cancer. Curr Opin Genet Dev 2000; 10: 157-161.
11. Modrich P. Strand-specific mismatch repair in mammalian cells. J Biol Chem 1997; 272: 24727-24730.
12. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002; 511: 145-178.
13. Hussein MR, Wood GS. Building bridges in cancer: mismatch repair and microsatellite instability. Am J Dermatopathol 2002; 24: 76-81.
14. Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol 2002; 3: 83-88.
15. Jass JR, Walsh MD, Barker M, Simms LA, Young J, Leggett BA. Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer 2002; 38(7): 858-866.
16. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 1993; 90: 6424-6428.
17. Koi M, Umar A, Chauhan DP, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduce N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994; 54: 4308-4312.
18. Carethers JM, Hawn MT, Chauhan DP, et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro-N-nitrosoguanide. J Clin Invest 1996; 98: 199-206.
19. D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998; 54: 334-341.
20. Aquilina G, Zijno A, Moscufo N, Dogliotti E, Bignami M. Tolerance to methylnitrosourea-induced DNA damage is associated with 6-thioguanine resistance in CHO cells. Carcinogenesis 1989; 10: 1219-1223.
21. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109-1111.
22. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with MutL and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996; 271: 19645-19648.
23. Anthoney DA, MacIlwrath AJ, Gallagher WM, Edlin ARM, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996; 56: 1374-1381.
24. McClay EF, Mastrangelo MJ. Systemic chemotherapy for malignant melanoma. Semin Oncol 1988; 15: 569-577.
25. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl -3-methyl-imidazo 5,1-d-1, 2, 3, 5-tetrazin - 4 (3H) -one (CCRG 81045; M&B 39831) a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846-5852.
26. Woll PJ, Crowther D, Johnson PWM, et al. Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 1995; 72: 183-184.
27. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995; 13: 910-913.
28. Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997; 40: 484-488.
29. Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 2001; 1: 13-19.
30. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer 1993; 29A: 940-942.
31. Giampietri A, Bonmassar E. Drug-induced modulation of immune responses in mice, effect of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC), and cyclo-phosphamide (Cy). J Immunopharmacol 1978; 1: 61-65.
32. Nardelli B, Puccetti P, Romani L, Sava G, Bonmassar E, Fioretti MC. Chemical xenogenization of routine lymphoma cells with triazene derivatives: immunotoxicological studies. Cancer Immunol Immunother 1984; 17: 213-217.
33. 6-Benzylguanine enhances the in vitro immunotoxic activity of Temozolomide on natural or antigen-dependent immunity J Pharmacol Exp Ther 1999; 291: 1292-1300.
34. Porcelli SA. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Ann Rev Immunol 1999; 17: 297-329.
35. Skopek TR, Liber HL, Penman BW and Thilly WG. Isolation of a human lymphoblastoid line heterozygous at the thymidine kinase locus: Possibility for a rapid human cell mutation assay. Biochem Biophys Res Commun 1978; 84: 411-416.
36. Goldmacher VS, Cuzick RA, Thilly WG. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-methyl-N′-nitro-N-nitrosoguanidine. J Biol Chem 1986; 261: 12462-12471.
37. Papadopoulos N, Nicolaides NC, Liu B, "et al.". Mutation of GTBP in genetically unstable cells. Science 1995; 268: 1915-1917.
38. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119: 203-210.
39. 6-alkylguanine alkyltransferase activity in Chinese hamster V79 cells following selection with chloroethylating agents. Carcinogenesis 1988; 9: 45-49.
40. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976; 72: 248-254.
41. D'Atri S, Romani L, Bonmassar E, et al. Untreated or drug-treated tumor cells are differentially recognized by allogeneic lymphocytes. Int J Immunopharmaco 1994; 16: 569-579.
42. 6-alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 1988; 15: 279-292.
43. Zlotogorski C, Erickson LC. Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts. Carcinogenesis 1984; 5: 83-87.
44. 6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 1991; 51: 619-623.
45. 6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: A phase I trial. Cancer Res 1992; 2: 2456-2459.
46. Lee SM, Margison GP, Woodcock AA, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993; 67: 1356-1360.
47. Aamadal S, Gerard B, Bohman T, D'Incalci M. Sequential administration of dacarbazine and fotemustine in patient with disseminated malignant melanoma: An effective combination with unexpected toxicity. Eur J Cancer 1992; 213: 447-450.
48. 6-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997; 3: 837-847.
49. Long L, Dolan ME. Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res 2001; 7: 4239-4244.
50. 6-alkylguanine-DNA-alkyltransferases. Curr Gene Ther 2002, 2: 1-8.
51. Galloway SM, Greenwood SK, Hill RS, Bradt CI, Bean CL. A role for mismatch repair in production of chromosome aberrations by methylating agents in human cells. Mutat Res 1995; 346: 231-245.
52. Karran P, Bignami M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res 1992; 20: 2933-2940.
53. Franchi A, Papa G, D'Atri S, Piccioni D, Masi M, Bonmassar E. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukaemia: a pilot study. Haematologica 1992; 77: 146-150.
54. Giuliani, A, Tentori L, Pepponi R, et al. Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3′-azido-3′-deoxythymidine. Pharmacol Res 1997; 35: 135-140.
55. Porcelli SA. The CD1 family: a third lineage of antigen-presenting molecules. Adv Immunol 1995; 59: 1-98.
56. Porcelli SA, Segelke BW, Sugita M, Wilson IA, Brenner MB. The CD1 family of lipid antigen-presenting molecules. Immunol Today 1998; 19: 362-368.
57. Moody DB, Besra GS. Glycolipid targets of CD1-mediated T-cell responses. Immunology 2001; 104: 243-251.
58. Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide. Cancer Res 1972; 32: 1450-1466.
59. Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A. Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc Natl Acad Sci USA 1970; 66: 1089-1095.
60. Fioretti MC, Bianchi R, Romani L, Bonmassar E. Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity. J Natl Cancer Inst 1983; 71: 1247-1251.
61. 6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. Cancer Res 1995; 55: 6231-6236.
62. Nardelli B, Puccetti P, Romani L, Sava G, Bonmassar E, Fioretti MC. Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies. Cancer Immunol Immunother 1984; 17: 213-217.